Pharmaceutical revenue of Merck & Co. by therapy class 2019

Merck and Co. generates the majority of its worldwide revenue from its pharmaceutical operating segment. Sales from the company’s oncology franchise, which focuses on drugs that treat cancer, accounted for the largest single share of its pharmaceutical revenue in 2019.

Revenues boosted by sales of cancer treatments

Merck & Co. is a global healthcare company that generated approximately 46.8 billion U.S. dollars in total revenue in 2019. The company has two reportable operating segments: pharmaceutical and animal health. The pharmaceutical segment is split into ten franchises - or therapeutic areas; the oncology franchise generated over 12 billion U.S. dollars in 2019 – a significant increase compared to the previous year. Sales of cancer drug Keytruda were particularly strong and increased from 7.17 billion in 2018 to over 11 billion U.S. dollars in 2019.

An overview of Merck’s global operations

The corporate headquarters of Merck & Co. is located in New Jersey, and the company’s domestic market is the region that continues to generate the most of its revenue. Outside of the United States, Merck & Co. has operations in Europe, the Middle East, Africa, Asia Pacific, and Latin America. The company’s sales in the Asia Pacific (excluding China and Japan) region stayed almost the same between 2017 and 2019. Operating business strategies in emerging markets, such as China, can come with challenges, but they offer huge potential for growth over time.